Forward-Looking StatementsAll statements in this press release about our expectations.

Clin Chem statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that could cause the actual results, performance or achievements of the company may differ materially from those expressed or implied by forward looking statements. Information on the information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the quarter ended March 2007, and all subsequent periodic reports with the SEC made. We assume no obligation and expressly disclaim any obligation to update forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events..

If the test shows tissue, so that that the man has prostate cancer , this calmed the man and his doctor and these repeat tests can be avoided. – PROGENSA PCA3 will limitations limitations of existing diagnostic tools , for example PSA , which usually do not increase, for reasons with cancer 6 As a result produces PSA test many false positive results, the inconvenient, expensive biopsies, In contrast, be unnecessary. In contrast, the genetic marker is PCA3 is increased only in cancerous prostate tissue, so that there is a specific indicator of cancer than PSA way reduce the number of unnecessary biopsies..The researchers suspect that improvement of infrastructure having limitations at car use, as car-free zones, traffic calming in a residential area, reductions in the motor vehicle speeds, and limit and more costly parking lot should be combined.